07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Aquaporin-4 (AQP4); corticotropin-releasing factor 1 (CRF1); corticotropin-releasing factor receptor 1 (CRHR1; CRFR1) Rat studies suggest...
07:00 , Oct 24, 2013 |  BC Innovations  |  Strategy

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...
07:00 , Mar 17, 2011 |  BC Innovations  |  Targets & Mechanisms

The hormone trigger in PTSD

Post-traumatic stress disorder is thought to involve changes in the circuitry of brain regions related to fear, although the specific molecular players have been elusive. Now, U.S. researchers have evidence that dysregulation of a brain...
07:00 , Oct 4, 2010 |  BioCentury  |  Finance

3Q approvals

3Q approvals Company Approval Abraxis BioScience Inc. (NASDAQ:ABII)/ Otsuka Pharmaceutical Co. Ltd. (Tokyo:4768) Japan approves Abraxane nab-paclitaxel to treat breast cancer Allergan Inc. (NYSE:AGN) EC approves Ozurdex dexamethasone intravitreal implant...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Clinical News

561679: Phase II data

Top-line data from 145 evaluable female patients in a double-blind, U.S. Phase II trial showed that 350 mg daily GSK561679 missed the primary endpoint of significantly improving Bech Melancholia scores, a measure of changes in...
23:50 , Sep 14, 2010 |  BC Extra  |  Clinical News

GSK561679 misses depression endpoint

Neurocrine Biosciences Inc. (NASDAQ:NBIX) said GSK561679 missed the primary endpoint in a double-blind U.S. Phase II trial to treat major depressive disorder (MDD). The corticotropin-releasing factor (CRF) receptor 1 antagonist did not significantly improve Bech...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Clinical News

561679: Phase II started

Neurocrine disclosed in its earnings that partner GlaxoSmithKline began a double-blind, placebo-controlled Phase II trial to evaluate oral 561679 in about 150 patients. The companies are developing CRF antagonists under a 2001 deal (see BioCentury,...
07:00 , Jun 28, 2010 |  BioCentury  |  Strategy

Indi-Plan B Takes Shape

Neurocrine Biosciences Inc. hopes a pair of recent deals will be transformational for the company in much the same way its 2002 indiplon partnership with Pfizer Inc. was for the biotech's last incarnation - but...
07:00 , Aug 20, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Anxiety Corticotropin-releasing factor (CRF);...
08:00 , Feb 16, 2009 |  BC Week In Review  |  Clinical News

561679: Phase II started

Neurocrine disclosed in its earnings that in 3Q08 partner GlaxoSmithKline began a 6-week, double-blind, placebo-controlled, U.S. Phase II trial (106139) of 561679 in 150 patients. The companies are developing CRF antagonists under a 2001 deal...